A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Phase 1 Completed 49 enrolled MedImmune LLC

NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety, tolerability and the tolerated maximum dose of MEDI-575 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.

Timeline

Start: 2009-03-02
Primary completion: 2012-01-19
Completion: 2012-01-19

Publications

Background Becerra CR, Conkling P, Vogelzang N, Wu H, Hong S, Narwal R, Liang M, Tavakkoli F, Pandya N. A phase I dose-escalation study of MEDI-575, a PDGFRalpha monoclonal antibody, in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Nov;74(5):917-25. doi: 10.1007/s00280-014-2567-9. Epub 2014 Aug 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TOVETUMAB	Monoclonal antibody	3 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	6 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	9 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	12 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	15 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	25 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	35 mg/kg	Intravenous

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Summary

Timeline

Publications

Drugs

Indications